Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.
- DAYBUE STIX powder formulation now broadly available in US for Rett syndrome
- FDA approval granted in December 2025, with initial limited launch in Q1 2026
- Over 80% caregiver satisfaction reported in early feedback
- Expert consensus supports trofinetide as part of standard care for Rett syndrome
- Neuren advancing NNZ-2591 clinical trials for multiple neurodevelopmental disorders
New Formulation Broadens Treatment Options
Neuren Pharmaceuticals (ASX:NEU) has announced that its partner Acadia Pharmaceuticals (Nasdaq: ACAD) has made DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide, broadly available in the United States for the treatment of Rett syndrome. The US Food and Drug Administration (FDA) approved this formulation in December 2025, with a limited launch occurring in the first quarter of 2026.
DAYBUE STIX is designed as an oral solution powder that caregivers can mix with various water-based liquids, such as juice or tea, allowing for tailored administration to suit patient preferences. The product’s individual packets enhance portability and convenience, addressing practical challenges faced by caregivers.
Positive Early Feedback and Expert Endorsement
Initial feedback from a small group of caregivers following the limited launch indicated that more than 80% expressed satisfaction with the new formulation, particularly valuing its flexibility and portability. This aligns with a recent expert consensus published by a steering group from International Rett Syndrome Foundation-designated centres of excellence, which recognised trofinetide oral solution as part of the standard of care for individuals with Rett syndrome.
Experts emphasised the importance of early initiation and sustained use of trofinetide, while also highlighting the need for individualized clinical decision-making to optimise outcomes for patients and their families. Dr Arthur Beisang from Gillette Children's Specialty Healthcare noted that DAYBUE STIX offers an additional flexible administration option that supports personalised care approaches.
Broader Context and Pipeline Developments
Neuren’s announcement follows a period of strong commercial momentum for the DAYBUE franchise, with the company reporting record royalties in early 2026. The full rollout of DAYBUE STIX is expected to continue through the second quarter of 2026, building on the limited initial launch phase. This expansion complements ongoing regulatory efforts, including Acadia’s recent push for a re-examination of trofinetide’s approval status in Europe, reflecting the company’s broader strategy to increase patient access globally.
Beyond DAYBUE, Neuren is advancing its second drug candidate, NNZ-2591, currently in Phase 3 clinical trials for neurodevelopmental disorders such as Phelan-McDermid syndrome. The program has received multiple orphan drug designations and fast track status from the FDA, underscoring its potential significance in addressing unmet medical needs.
For investors and observers, these developments underscore Neuren’s dual focus on commercialising its existing FDA-approved treatment while progressing its pipeline of novel therapies for serious neurological conditions.
Further details on Neuren’s royalty growth and commercial outlook can be found in the company’s recent report on DAYBUE royalties and sales guidance.
Bottom Line?
The broad US availability of DAYBUE STIX introduces a flexible treatment option for Rett syndrome, with early positive feedback and expert support, while Neuren continues to advance its neurodevelopmental disorder pipeline.
Questions in the middle?
- How will the broader rollout of DAYBUE STIX impact overall patient uptake and sales in the US market?
- What are the prospects and timelines for regulatory approval and commercialisation of trofinetide in Europe following Acadia’s re-examination request?
- How might ongoing clinical trial results for NNZ-2591 influence Neuren’s future growth and treatment portfolio?